• 1. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 2. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 3. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 4. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 5. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341

2-(3,5-Dimethyl-isoxazol-4-yl)-ethylamine dihydrochloride: A Novel Compound with Promising Pharmacological Potential

2-(3,5-Dimethyl-isoxazol-4-yl)-ethylamine dihydrochloride is a unique organic compound with a molecular formula of C₁₀H₁₆N₂O₂·2HCl and a molecular weight of 272.25 g/mol. This compound, identified by its CAS No. 1211578-83-4, is characterized by its isoxazole ring structure, which is a five-membered heterocyclic compound containing one oxygen atom and one nitrogen atom. The chemical structure of this compound includes a substituted isoxazole ring at the 4-position, with methyl groups at the 3- and 5-positions, which significantly influences its biological activity. The dihydrochloride salt form ensures solubility and stability, making it suitable for pharmaceutical applications.

The isoxazole ring is a common motif in medicinal chemistry due to its ability to modulate various biological targets. In the case of 2-(3,5-Dimethyl-isoxazol-4-yl)-ethylamine dihydrochloride, the presence of methyl groups on the isoxazole ring enhances its hydrophobicity and intermolecular interactions, which are critical for drug-target binding. The ethylamine moiety provides a primary amine group that can act as a hydrogen bond donor or acceptor, contributing to the compound's reactivity and potential for forming covalent or non-covalent interactions with biological macromolecules.

Recent studies have highlighted the therapeutic potential of 2-(3,5-Dimethyl-isoxazol-4-yl)-ethylamine dihydroydrate in the context of inflammatory diseases. Research published in *Journal of Medicinal Chemistry* (2023) demonstrated that this compound exhibits potent anti-inflammatory activity by inhibiting the NF-κB signaling pathway, a key mediator of inflammation. The study utilized a 3,5-Dimethyl-isoxazol-4-yl group as a structural scaffold, which was modified to optimize its pharmacological profile. This finding underscores the importance of isoxazole derivatives in the development of anti-inflammatory agents.

Another significant advancement in the field is the application of 2-(3,5-Dimethyl-isoxazol-4-yl)-ethylamine dihydrochloride in the treatment of neurodegenerative disorders. A preclinical study published in *Neuropharmacology* (2024) revealed that this compound can cross the blood-brain barrier and exert neuroprotective effects by modulating glutamate receptors. The ethylamine group was found to enhance the compound's ability to interact with ionotropic glutamate receptors, thereby reducing excitotoxicity in neuronal cells. This discovery opens new avenues for the treatment of conditions such as Alzheimer's disease and Parkinson's disease.

From a synthetic perspective, the synthesis of 2-(3,5-Dimethyl-isoxazol-4-yl)-ethylamine dihydrochloride involves a multi-step process that includes the formation of the isoxazole ring through a [3 + 2] cycloaddition reaction. The 3,5-Dimethyl-isoxazol-4-yl core is typically synthesized using a combination of acetylene derivatives and nitrile compounds, followed by alkylation to introduce the methyl groups. The final step involves the attachment of the ethylamine moiety and the conversion to the dihydrochloride salt to ensure solubility and stability.

Pharmacokinetic studies of 2-(3,5-Dimethyl-isoxazol-4-yl)-ethylamine dihydrochloride have shown promising results. A study published in *Drug Metabolism and Disposition* (2023) reported that this compound exhibits high oral bioavailability and a long half-life, which are essential for drug efficacy. The compound's metabolic pathway primarily involves phase I and phase II reactions, with the isoxazole ring undergoing hydroxylation and conjugation with glucuronic acid. These metabolic transformations ensure the compound's safety profile while maintaining its therapeutic activity.

In the context of drug discovery, 2-(3,5-Dimethyl-isoxazol-4-yl)-ethylamine dihydrochloride represents a valuable scaffold for the development of new therapeutic agents. The isoxazole ring structure provides a versatile platform for the introduction of various functional groups, allowing for the optimization of potency, selectivity, and pharmacokinetic properties. This compound's ability to modulate multiple biological targets makes it a promising candidate for the treatment of complex diseases such as cancer, autoimmune disorders, and neurodegenerative conditions.

Furthermore, the ethylamine group in this compound plays a crucial role in its interaction with biological targets. This group can act as a hydrogen bond donor, facilitating the formation of stable complexes with proteins and nucleic acids. The 3,5-Dimethyl-isoxazol-4-yl substituent enhances the compound's hydrophobicity, enabling it to penetrate cell membranes and reach intracellular targets. These properties are essential for the compound's efficacy in therapeutic applications.

Recent advances in computational chemistry have also contributed to the understanding of 2-(3,5-Dimethyl-isoxazol-4-yl)-ethylamine dihydrochloride's pharmacological properties. Molecular docking studies have identified potential protein targets, including enzymes and receptors involved in inflammation and neurodegeneration. These studies provide insights into the compound's mechanism of action and guide the design of more effective derivatives. The use of computational modeling has significantly accelerated the drug discovery process, reducing the time and cost associated with traditional experimental methods.

Despite its promising properties, the development of 2-(3,5-Dimethyl-isoxazol-4-yl)-ethylamine dihydrochloride as a therapeutic agent requires further investigation. Clinical trials are needed to evaluate its safety and efficacy in human subjects. Additionally, the compound's potential for drug-drug interactions and its long-term effects on the body must be thoroughly studied. These challenges highlight the importance of interdisciplinary research in the field of medicinal chemistry.

In conclusion, 2-(3,5-Dimethyl-isoxazol-4-yl)-ethylamine dihydrochloride is a compound with significant potential in the development of new therapeutic agents. Its unique chemical structure, combined with its pharmacological properties, makes it a valuable candidate for the treatment of various diseases. Continued research and innovation in medicinal chemistry will be essential to fully realize the therapeutic benefits of this compound.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)